D-ValinolCAS# 4276-09-9 |
- Mc-MMAD
Catalog No.:BCC1735
CAS No.:1401963-15-2
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- CYT997 (Lexibulin)
Catalog No.:BCC4601
CAS No.:917111-44-5
- MPC 6827 hydrochloride
Catalog No.:BCC8040
CAS No.:917369-31-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 4276-09-9 | SDF | Download SDF |
PubChem ID | 6950587 | Appearance | Powder |
Formula | C5H13NO | M.Wt | 103.1 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R)-2-amino-3-methylbutan-1-ol | ||
SMILES | CC(C)C(CO)N | ||
Standard InChIKey | NWYYWIJOWOLJNR-YFKPBYRVSA-N | ||
Standard InChI | InChI=1S/C5H13NO/c1-4(2)5(6)3-7/h4-5,7H,3,6H2,1-2H3/t5-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
D-Valinol Dilution Calculator
D-Valinol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 9.6993 mL | 48.4966 mL | 96.9932 mL | 193.9864 mL | 242.483 mL |
5 mM | 1.9399 mL | 9.6993 mL | 19.3986 mL | 38.7973 mL | 48.4966 mL |
10 mM | 0.9699 mL | 4.8497 mL | 9.6993 mL | 19.3986 mL | 24.2483 mL |
50 mM | 0.194 mL | 0.9699 mL | 1.9399 mL | 3.8797 mL | 4.8497 mL |
100 mM | 0.097 mL | 0.485 mL | 0.9699 mL | 1.9399 mL | 2.4248 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
D-Valinol
- 2-Aminophenyl phenyl sulfone
Catalog No.:BCC8554
CAS No.:4273-98-7
- Pedunculoside
Catalog No.:BCN1191
CAS No.:42719-32-4
- Cyproterone Acetate
Catalog No.:BCC3758
CAS No.:427-51-0
- S-Isopropylisothiourea hydrobromide
Catalog No.:BCC6837
CAS No.:4269-97-0
- NS 5806
Catalog No.:BCC7872
CAS No.:426834-69-7
- 4-Hydroxy-3-methoxyphenyl O-beta-D-6-O-syringate-glucopyranoside
Catalog No.:BCN1442
CAS No.:426821-85-4
- Hemapolin
Catalog No.:BCC8994
CAS No.:4267-80-5
- Dehydrodiconiferyl alcohol
Catalog No.:BCN6878
CAS No.:4263-87-0
- 21,23-Dihydro-23-hydroxy-21-oxozapoterin
Catalog No.:BCN7230
CAS No.:426266-88-8
- TAK-700 salt
Catalog No.:BCC1979
CAS No.:426219-53-6
- TAK-700 (Orteronel)
Catalog No.:BCC2280
CAS No.:426219-18-3
- Luteolin-6-C-glucoside
Catalog No.:BCN4985
CAS No.:4261-42-1
- Magnoflorine Iodide
Catalog No.:BCN2911
CAS No.:4277-43-4
- H-N-Me-Leu-OBzl.TosOH
Catalog No.:BCC3215
CAS No.:42807-66-9
- Shinjulactone L
Catalog No.:BCN7958
CAS No.:4283-49-2
- Catechin 7-xyloside
Catalog No.:BCN5484
CAS No.:42830-48-8
- Flumequine
Catalog No.:BCC5090
CAS No.:42835-25-6
- Flumequine sodium
Catalog No.:BCC8985
CAS No.:42835-68-7
- H-Ala-OBzl.TosOH
Catalog No.:BCC3191
CAS No.:42854-62-6
- 2-(3-Benzoylphenyl)propionitrile
Catalog No.:BCC8479
CAS No.:42872-30-0
- For-Met-OH
Catalog No.:BCC2992
CAS No.:4289-98-9
- 14-Deoxy-11,12-didehydroandrographolide
Catalog No.:BCN1441
CAS No.:42895-58-9
- Santamarine
Catalog No.:BCN5485
CAS No.:4290-13-5
- Tilianin
Catalog No.:BCN3669
CAS No.:4291-60-5
Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines.[Pubmed:23212614]
Mol Biol Rep. 2013 Mar;40(3):2205-13.
Chronic myeloid leukemia (CML) is characterized by the presence of p210(Bcr-Abl) which exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the treatment of CML. Despite high rates of clinical response, CML patients can develop resistance against these kinase inhibitors mainly due to point mutations within the Abl protein kinase domain. Previously, we have identified oleic acid as the active component in the mushroom Daedalea gibbosa that inhibited the kinase activity of Bcr-Abl. Here, we report that the oleyl amine derivatives, S-1-(1-Hydroxymethyl-2-methyl-propyl)-3-octadec-9-enyl-urea [oleylaminocarbonyl-L-N-valinol,oroleylaminocarbonyl-S-2-isopropyl-N-ethanolamine ,oleylamine-carbonyl-L-valinol] (cpd 6) and R-1-(1-Hydroxymethyl-2-methyl-propyl)-3-octadec-9-enyl-urea [oleylamineocarbonyl-D-N-valinol, oleylaminocarbonyl-R-2-isopropyl-N-ethanolamine, or oleylamine-carbonyl-D-Valinol] (cpd 7), inhibited the activity of the native and T315I mutated Bcr-Abl. Furthermore, cpd 6 and 7 exhibited higher activity towards the oncogenic Bcr-Abl in comparison to native c-Abl in SupB15 Ph-positive ALL cell line.